Packaging, storage and distribution of schedule I – V controlled substance is now a fully functional capability of Almac’s new North American Headquarters facility in Souderton PA.
For the first time, pluripotent stem cells have been generated from horses. Because horses' muscle and tendon systems are similar to our own, this may aid the development of preclinical models leading to human applications.
In Europe and the USA, 10% of treatment-naïve patients are infected with transmitted drug resistant (TDR) HIV that already has at least one drug-resistant mutation. These patients are more than three times as likely to experience treatment failure.
Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, announced plans to collaborate with Medtronic, Inc. on the clinical development of Nile’s proprietary natriuretic peptide, cenderitide, for heart failure and renal disease applications.
Shire plc submitted a complete response to the not approvable letter issued by the US Food and Drug Administration to Jerini AG in April 2008 regarding its New Drug Application for FIRAZYR for the treatment of acute attacks of hereditary angioedema.
Shocking as it may seem, U.S. government doctors once thought it was fine to experiment on disabled people and prison inmates. Much of this horrific history is 40 to 80 years old, but it is the backdrop for a meeting in Washington this week by a presidential bioethics commission.
Depomed Inc. said it received a previously announced payment of $48 million from Abbott Laboratories for the Food and Drug Administration's approval of Gralise, which treats pain following the viral infection shingles.
Protalix BioTherapeutics Inc. said the Food and Drug Administration asked for more information on the company's potential Gaucher disease drug. The company is seeking FDA approval for taliglucerase alfa for the treatment of Gaucher disease.
Eli Lilly and Co. will pay a $337,500 penalty to settle a federal complaint accusing one of the drugmaker's facilities of violating the Clean Air Act. A lawsuit filed by the federal government described the Lilly Technology Center in Indianapolis as a "major source" of pollution.
Health care giant Johnson & Johnson raised Chief Executive William Weldon's salary but cut his annual bonus for 2010, after two years of revenue declines and an unprecedented string of recalls involving Tylenol and other household medicines.
Hefty special charges caused a fourth-quarter loss at Bayer AG, though the pharmaceutical and chemical company said that revenues rose by 14.5 percent, led by increasing sales of high-tech materials and agricultural products.
The patent system hasn't changed much since 1952 when Sony was coming out with its first pocket-size transistor radio. Now, after years of trying, Congress may be about to do something about that.
Sigma Life Science, the biological products and services research business of Sigma-Aldrich, announced the release of its pre-designed CompoZr Knockout Zinc Finger Nucleases technology to knockout any gene in the human genome.
The Infinium HD FFPE Restore Kit from Illumina enables researchers to repair damaged DNA and perform whole-genome genotyping on highly degraded formalin-fixed and paraffin embedded samples that up to now have been largely unusable to produce high-quality data.
Lexicon Pharmaceuticals Inc.'s fourth-quarter loss widened on higher costs and lower revenue from partnerships, the drug developer said. The company reported a net loss of $23 million.